Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells
Sponsor: Meir Medical Center
ClinicalTrials ID:NCT01267461
This study investigates the biological effects of insulin analogues on primary tumor cells from endometrial and colon cancer patients. Eligible participants are those diagnosed with these cancers. Tumor tissue samples will be collected from patients at Meir Medical Center's Gynecologic Oncology and Gastrointestinal Departments for analysis.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Recently the general medical literature has become aware that the use of certain long-acting insulin analogues could potentially increase cancer risk.During the last few years the investigators group generated information of both scientific and clinical relevance on the proliferative and anti-apoptotic actions of insulin analogues. The goal of this project is to evaluate the hypothesis that the proliferative and signalling activities elicited by insulin analogues may have a impact on tumor behavior. In this study the investigators will asses the biological actions of insulin analogs in primary tumor cells of endometrial and colon cancer.
Eligibility Criteria
Inclusion Criteria
- Patients with Endometrial and Colon Cancer
Exclusion Criteria
- None
Get This Program In Your Inbox
You can sign up and apply your patients for this program.